PROCEPT BioRobotics (PRCT) Scheduled to Post Quarterly Earnings on Wednesday

PROCEPT BioRobotics (NASDAQ:PRCT) is set to post its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect PROCEPT BioRobotics to post earnings of ($0.55) per share for the quarter. PROCEPT BioRobotics has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative net margin of 77.75% and a negative return on equity of 46.59%. The company had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.79 million. During the same quarter in the prior year, the company earned ($0.56) EPS. The business’s revenue was up 83.3% on a year-over-year basis. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $51.83 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.63 and a quick ratio of 6.77. PROCEPT BioRobotics has a 1 year low of $24.83 and a 1 year high of $54.79. The company has a market capitalization of $2.66 billion, a PE ratio of -23.14 and a beta of 1.01. The company has a fifty day moving average of $49.33 and a two-hundred day moving average of $42.77.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wells Fargo & Company upped their price objective on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Truist Financial upped their price objective on shares of PROCEPT BioRobotics from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Buy” and a consensus price target of $46.00.

Insider Activity

In other news, CFO Kevin Waters sold 904 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $50.00, for a total value of $45,200.00. Following the completion of the sale, the chief financial officer now directly owns 33,523 shares of the company’s stock, valued at $1,676,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Kevin Waters sold 904 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $50.00, for a total transaction of $45,200.00. Following the completion of the transaction, the chief financial officer now directly owns 33,523 shares of the company’s stock, valued at $1,676,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Reza Zadno sold 5,391 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $48.83, for a total transaction of $263,242.53. Following the transaction, the chief executive officer now directly owns 241,319 shares of the company’s stock, valued at $11,783,606.77. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,149 shares of company stock valued at $4,653,720. Insiders own 19.60% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).